Shlee Song, MD
Vascular Neurology · West Hollywood, CANPI 1871753525
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,639 of the $6,222 with a category attached, or 90.6%. AstraZeneca accounts for 90.6% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2021 at $5,705 and has fallen 99.8% since, to $13 in 2025.
Across 13 payments — averaging $478.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$6K
- Genentech, Inc.$425
- Stryker$106
- Medtronic$23
- Penumbra, Inc.$15
- Life Molecular Imaging Ltd$13
Across 35 payments — averaging $3945.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$138K
What the payments were for
- Consulting fees$5,63991%
- Food & beverage$5839%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 3 | $5,639 |
| Genentech, Inc. | 6 | $425 |
| Stryker | 1 | $106 |
| Medtronic | 1 | $23 |
| Penumbra, Inc. | 1 | $15 |
| Life Molecular Imaging Ltd | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,222 in reported general payments places this provider in the 75th percentile of 58 vascular neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 12 | $7,685 |
| Atorvastatin Calcium | 22 | $163 |
Paid to pharmacies, not to this prescriber.
Other vascular neurology in West Hollywood
- Konrad SchlickWest Hollywood$28
- Gregory AlbersStanford$415K
- Chitra VenkatasubramanianStanford$260K
- Shuichi SuzukiArcadia$126K
- Royya ModirSan Diego$113K
- Maarten LansbergStanford$86K
- Muhammad TaqiPalm Springs$77K
- Ashish NandaFullerton$66K
- Andrew XavierMountain View$46K
- Sarah LeeStanford$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.